Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide in nuclear DNA primary mitochondrial disease
NL-OMON51595Phase 3Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Jan 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Mitochondriopathy comparing Elamipretide with Placebo (2 arms). Primary endpoint: 6-Minute Walk Test distance. Started Jan 2023; status: completed.
02
Drugs
elamipretide
03
Conditions
Mitochondriopathy
Beyond the preview
Go deeper on NL-OMON51595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51595.